THE NEXT
EVOLUTION IN
CELLULAR
MEDICINE
Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.
BEST IN CLASS & SCALABLE
Cellular Medicine manufacturing
Featuring industry leading and diverse product lines
ALLOGENEIC PLATFORM
Built on two decades of science
Driven by a deep, seasoned management team
OUR MISSION
is to lead the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at unparalleled scale, quality, and economics
OUR VISION
Harness the Unique Biology & Ready Availability of the Placenta
- Unmet Global NeedSignificant unmet global need for allogeneic cellular medicines delivered on-demand, off-the-shelf
- Groundbreaking ResearchGroundbreaking basic & translational research into the unique biological activity of placental-derived cells
- Pioneering TechnologyPioneering technology platform of placental-derived cellular medicines and advanced biomaterials
- Industry TimingThe time has arrived for cellular medicines that overcome barriers of scale, quality, and economics
Cellular Medicine Manufacturing
The Process is the Product
A fully integrated, purpose-built manufacturing, translational research and biobanking center
- Purpose built facility staffed by over 100 highly specialized scientists, engineers & technicians
- 150,000sq ft including laboratory and advanced manufacturing space for cellular medicine & biomaterials
- Clinical Scale – (9) Grade C/ISO 7 suites and (6) Grade D/ISO 8 labs ALL GMP-CAPABLE
The Latest From Our
NEWSROOM
Celularity Inc. expansion is driven by experienced Cellular Medicine leaders & innovators with deep expertise in clinical development & regulatory approval.
Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update
Celularity Founder, Chairman and Chief Executive Officer, Robert J. Hariri, M.D., Ph.D., Dually Awarded for Pioneering Contributions in Medicine and Leadership
Celularity and Arthrex Enter into Exclusive Supply and Distribution Agreement for Multiple Commercial Products
Celularity Announces Expansion of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) Phase 1 Trial in Patients with Acute Myeloid Leukemia